Sage Therapeutics Inc. (SAGE)
NASDAQ: SAGE
· Real-Time Price · USD
8.68
0.00 (0.00%)
At close: Jul 30, 2025, 3:59 PM
0.00% (1D)
| Bid | 8.67 |
| Market Cap | 544.94M |
| Revenue (ttm) | 70.41M |
| Net Income (ttm) | -301.19M |
| EPS (ttm) | -4.89 |
| PE Ratio (ttm) | -1.7750511247443763 |
| Forward PE | -3.21 |
| Analyst | Hold |
| Dividends | n/a |
| Ask | 8.8 |
| Volume | 17,394,354 |
| Avg. Volume (20D) | 2,480,352 |
| Open | 8.68 |
| Previous Close | 8.68 |
| Day's Range | 8.68 - 8.68 |
| 52-Week Range | 4.62 - 9.36 |
| Beta | 0.30 |
| Ex-Dividend Date | n/a |
About SAGE
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol SAGE
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for SAGE stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsEarnings Surprise
Sage Therapeutics has released their quartely earnings
on Jul 30, 2025:
Sage Therapeutics Inc. is scheduled to release its earnings on
Oct 28, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 months ago
+35.37%
Sage Therapeutics shares are trading higher after ...
Unlock content with
Pro Subscription
8 months ago
+35.14%
Sage Therapeutics shares are trading higher after the company confirmed the receipt of an unsolicited, nonbinding proposal from Biogen to acquire all outstanding shares not already owned by Biogen for $7.22 per share.
